New MGA Analysis of the Adalimumab Biosimilars Market in the United States
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
Alex Brill joined CNBC’s Squawk Box to discuss Biden’s billionaire tax policy proposal and why it is not desirable for the U.S. economy.
“The patent dance, under current law, places no limits on the number of patents that a branded biologics maker can claim – abusing laws enacted by Congress in 2010 intended to ease biosimilar entry.”
“Given the long-term success of Humira, which can cost patients up to $84,000 a year, initial uptake of the biosimilars may be limited, said Alex Brill, founder and CEO of economic policy consulting firm Matrix Global Advisors.”
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”